Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MR Scanning of Very Young Children With Severe Developmental Disorders

This study has been completed.
Sponsor:
Collaborators:
Netherlands Organisation for Scientific Research
The Dutch Brain Foundation
Information provided by:
UMC Utrecht
ClinicalTrials.gov Identifier:
NCT00156221
First received: September 8, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
  Purpose

The specific is to study the MR morphologic and spectroscopic brain correlates and predictors of development in children with severe developmental disorders (autistic spectrum disorders and/or mental retardation and/or language disorders). Given the frequently observed association of autism with known medical conditions, particularly in cases with comorbid mental retardation and in cases with atypical autism (Rutter et al., 1994; Gillberg, 1995), children with suspected autism or related developmental disorders will be asked to participate in an extensive state of the art laboratory work-up which includes T1 and T2 weighted MRI of the brain. MRI data will be analyzed both qualitatively, looking for focal abnormalities and degree of myelination, and quantitatively, measuring volumes of total brain, cerebellum, ventricles and grey and white matter. For research purposes, the work-up will be supplied with proton Magnetic Resonance Spectroscopy (MRS) of the brain. This data set provides the opportunity to chart brain-behavior relationships in young children with suspected autism and related PDD cross-sectionally.


Condition
Autism
Mental Retardation
Language Disorder

Study Type: Observational
Study Design: Observational Model: Natural History
Time Perspective: Cross-Sectional
Official Title: MR Scanning of Very Young Children With Severe Developmental Disorders (Autistic Spectrum Disorders and/or Mental Retardation and/or Language Disorders)

Resource links provided by NLM:


Further study details as provided by UMC Utrecht:

Study Start Date: September 2000
Estimated Study Completion Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Months to 7 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 months to 7 years
  • Diagnosis of autism spectrum disorder, a language disorder or mental retardation

Exclusion Criteria:

  • Significant motor or sensory impairment
  • Major physical abnormalities
  • History of serious head injury
  • Identifiable neurologic disorder
  • Metal implants
  • Contraindication for MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00156221

Locations
Netherlands
UMC Utrecht
Utrecht, Netherlands, 3508 GA
Sponsors and Collaborators
UMC Utrecht
Netherlands Organisation for Scientific Research
The Dutch Brain Foundation
Investigators
Study Chair: Herman van Engeland, PhD, MD UMC Utrecht
Principal Investigator: Mijke Zeegers, Msc UMC Utrecht
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00156221     History of Changes
Other Study ID Numbers: METC UMC Utrecht 99/184
Study First Received: September 8, 2005
Last Updated: September 8, 2005
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by UMC Utrecht:
Autism
MRI
Developmental Disorders

Additional relevant MeSH terms:
Developmental Disabilities
Disease
Intellectual Disability
Language Disorders
Communication Disorders
Mental Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Pathologic Processes
Signs and Symptoms

ClinicalTrials.gov processed this record on November 27, 2014